Effect of Nanoparticle Rigidity on the Interaction of Stromal Membrane Particles with Leukemia Cells.

Jun 09, 2025

Experts: Sander de Weerd,Xinyu Ma,Zahra Zohali,Lieve L Oudejans,Emmanouil Kyrloglou,Marc C A Stuart,Wouter H Roos,Jan Jacob Schuringa,Anna Salvati

In acute myeloid leukemia (AML), disease relapse is often observed because of therapy-resistant leukemic stem cells that re-initiate the disease. Leukemic stem cells can tightly associate with mesenchymal stromal cells inside the bone marrow, which is considered to further drive drug resistance. Here, the cell membrane of bone marrow stromal cells is used to prepare cell membrane nanoparticles and study their interactions with AML cells. Cell membrane liposomes (CM-Liposomes) of different charge are prepared and either used directly, or after deposition on silica cores to modulate nanoparticle mechanical properties. Nanoparticle size, zeta potential and coating efficiency are analyzed by dynamic light scattering (DLS) and cryo electron microscopy (Cryo-EM) imaging. Atomic force microscopy (AFM) is used to characterize the mechanical properties of CM-Liposomes and confirm bilayer deposition on silica cores. Finally, uptake by leukemic cells is determined. No difference in uptake is found between soft CM-Liposomes and liposomes of the same composition without membrane components. Instead, after deposition on a rigid core, uptake is higher for the cell membrane particles. Preliminary results on primary cells from leukemia patients confirm this observation. These results show that nanoparticle rigidity strongly affects the interaction between cell membrane nanoparticles and the targeted cells.
© 2025 The Author(s). Advanced Healthcare Materials published by Wiley‐VCH GmbH.

Author

admin

View all posts

ABOUT THE EXPERTS

Sander de Weerd,Xinyu Ma,Zahra Zohali,Lieve L Oudejans,Emmanouil Kyrloglou,Marc C A Stuart,Wouter H Roos,Jan Jacob Schuringa,Anna Salvati

Sander de Weerd

Nanomedicine and Drug Targeting, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, Groningen, 9713 AV, The Netherlands.

Molecular Biophysics, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 3, Groningen, 9747 AG, The Netherlands.

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, 9713 GZ, The Netherlands.

Xinyu Ma

Nanomedicine and Drug Targeting, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, Groningen, 9713 AV, The Netherlands.

Zahra Zohali

Nanomedicine and Drug Targeting, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, Groningen, 9713 AV, The Netherlands.

Lieve L Oudejans

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, 9713 GZ, The Netherlands.

Emmanouil Kyrloglou

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, 9713 GZ, The Netherlands.

Marc C A Stuart

Electron Microscopy, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 7, Groningen, 9747 AG, The Netherlands.

Wouter H Roos

Molecular Biophysics, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 3, Groningen, 9747 AG, The Netherlands.

Jan Jacob Schuringa

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, 9713 GZ, The Netherlands.

Anna Salvati

Nanomedicine and Drug Targeting, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, Groningen, 9713 AV, The Netherlands.